The effect of the AN69 ST100 versus oXiris ® membrane on filter life during CRRT for non-anticoagulated liver failure patients.

BACKGROUNDS: In patients with liver failure, continuous renal replacement therapy (CRRT) without anticoagulation may be necessary. A new heparin coated membrane (oXiris® ) may prolong circuit life in this setting.

OBJECTIVES: In liver failure patients not receiving anticoagulation, to compare CRRT circuit life with the oXiris® versus the AN69 ST100 (usual care) membrane.

METHODS: Randomized single cross-over trial.

RESULTS: We studied 20 patients and 39 circuits. Twenty-five treatments used femoral and 14 internal jugular access catheters. Median circuit life was 21 h (IQR: 8.25-35.5) with the AN69 versus 16.0 h (14-25) with the oXiris® membrane ( p  = 0.36). Median first circuit duration was 14 (11.25-23) h for the AN69 ST100 versus 16 (8 -26) for the oXiris® membrane. There was also no difference between the AN69 ST100 or oXiris® membrane circuits using femoral access at 13 (8 -22.5) versus 15.5 (12.5-21.5) h ( p  = 0.57) or internal jugular access at 28 (13-47) versus 23 (21-29) h ( p  = 0.79), respectively.

CONCLUSIONS: The oXiris® heparin-grafted membrane does not appear to prolong circuit life in liver failure patients receiving CRRT without anticoagulation.